Nutrien (NYSE:NTR – Get Free Report)‘s stock had its “equal weight” rating reiterated by Barclays in a note issued to investors on Tuesday, Marketbeat.com reports. They presently have a $56.00 price objective on the stock, up from their prior price objective of $55.00. Barclays‘s price target would indicate a potential upside of 6.44% from the company’s current price.
NTR has been the topic of a number of other reports. Piper Sandler upgraded shares of Nutrien from an “underweight” rating to an “overweight” rating and lifted their price objective for the company from $50.00 to $58.00 in a research note on Monday, January 13th. Oppenheimer started coverage on Nutrien in a report on Thursday, December 12th. They set an “outperform” rating and a $60.00 target price on the stock. Wells Fargo & Company downgraded shares of Nutrien from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $62.00 to $50.00 in a report on Tuesday, September 24th. CIBC reiterated an “outperformer” rating and issued a $55.00 target price (down from $60.00) on shares of Nutrien in a report on Tuesday, December 10th. Finally, Raymond James upgraded shares of Nutrien from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $58.00 to $60.00 in a report on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, Nutrien has an average rating of “Moderate Buy” and a consensus price target of $58.39.
Check Out Our Latest Report on NTR
Nutrien Stock Up 2.6 %
Nutrien (NYSE:NTR – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.39 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.04). Nutrien had a return on equity of 6.99% and a net margin of 2.79%. The business had revenue of $5.35 billion for the quarter, compared to analyst estimates of $5.26 billion. During the same quarter in the prior year, the firm posted $0.35 earnings per share. The business’s quarterly revenue was down 5.0% on a year-over-year basis. As a group, sell-side analysts predict that Nutrien will post 3.5 EPS for the current year.
Institutional Investors Weigh In On Nutrien
Several institutional investors and hedge funds have recently modified their holdings of NTR. Central Pacific Bank Trust Division bought a new position in shares of Nutrien in the third quarter valued at approximately $28,000. Exchange Traded Concepts LLC increased its holdings in Nutrien by 96.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 846 shares of the company’s stock valued at $38,000 after buying an additional 416 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Nutrien in the second quarter valued at about $52,000. Union Bancaire Privee UBP SA bought a new stake in shares of Nutrien in the 4th quarter valued at approximately $67,000. Finally, Larson Financial Group LLC lifted its holdings in Nutrien by 1,370.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,603 shares of the company’s stock valued at $77,000 after purchasing an additional 1,494 shares during the last quarter. Institutional investors and hedge funds own 63.10% of the company’s stock.
Nutrien Company Profile
Nutrien Ltd. provides crop inputs and services. The company operates through four segments: Retail, Potash, Nitrogen, and Phosphate. The Retail segment distributes crop nutrients, crop protection products, seeds, and merchandise products. The Potash segment provides granular and standard potash products.
Recommended Stories
- Five stocks we like better than Nutrien
- How is Compound Interest Calculated?
- Oracle Announces Game-Changing News for the AI Industry
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Why Invest in 5G? How to Invest in 5G Stocks
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Nutrien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutrien and related companies with MarketBeat.com's FREE daily email newsletter.